Prostate Artery Embolization in Patients with Prostate Volumes of 80 mL or More: A Single-Institution Retrospective Experience of 93 Patients

Shivank Bhatia, Vishal K. Sinha, Sardis Harward, Christopher Gomez, Bruce Kava, Dipen J Parekh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To evaluate the safety and efficacy of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia for prostates ≥ 80 mL. Patients and Methods: A retrospective review was conducted of 93 patients with prostate volumes (PVs) ≥ 80 mL treated with PAE from April 2014 through October 2017. Mean patient age was 68.5 years (range 52–88) and mean age-adjusted Charlson comorbidity index was 3.2 (range 1–8). Exclusion criteria included history of biopsy-proven prostate cancer or catheter dependency. Clinical and urodynamic outcomes were reviewed at 1, 3, 6, and 12 months. Adverse events were graded according to the Clavien-Dindo classification. Results: Mean PV decreased significantly from 141.7 mL to 98.1 mL at 3 months (P <.01) and 82.2 mL at 12 months (P <.01). Significant improvements were seen in 3- and 12-month mean International Prostate Symptom Scores (IPSS) (22.3 vs 7.1 and 7.3, respectively; P <.01 for both), quality of life (QOL) (4.4 vs 1.2 and 1.3; P <.01 for both), and postvoid residual volume (196.7mL vs 92.1 and 61.2 mL; P <.01 and P <.01, respectively). Significant improvement was also seen in 3-month mean maximum urinary flow: 7.7 mL/s vs 12.8 mL/s (P <.01). One grade II complication of stroke occurred; all other complications were self-limited and grade I. Conclusions: PAE achieved a clinically and statistically significant improvement in symptom burden and secondary outcome measures in patients with PVs ≥ 80 mL. PAE may be an alternate treatment for patients for whom conventional surgical options are limited or associated with significant morbidity.

Original languageEnglish (US)
Pages (from-to)1392-1398
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume29
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Prostate
Arteries
Residual Volume
Urodynamics
Prostatic Hyperplasia
Comorbidity
Prostatic Neoplasms
Catheters
Stroke
Quality of Life
Outcome Assessment (Health Care)
Morbidity
Biopsy
Safety
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

@article{c04b0858d2be4bfaa1399a1040eb8495,
title = "Prostate Artery Embolization in Patients with Prostate Volumes of 80 mL or More: A Single-Institution Retrospective Experience of 93 Patients",
abstract = "Purpose: To evaluate the safety and efficacy of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia for prostates ≥ 80 mL. Patients and Methods: A retrospective review was conducted of 93 patients with prostate volumes (PVs) ≥ 80 mL treated with PAE from April 2014 through October 2017. Mean patient age was 68.5 years (range 52–88) and mean age-adjusted Charlson comorbidity index was 3.2 (range 1–8). Exclusion criteria included history of biopsy-proven prostate cancer or catheter dependency. Clinical and urodynamic outcomes were reviewed at 1, 3, 6, and 12 months. Adverse events were graded according to the Clavien-Dindo classification. Results: Mean PV decreased significantly from 141.7 mL to 98.1 mL at 3 months (P <.01) and 82.2 mL at 12 months (P <.01). Significant improvements were seen in 3- and 12-month mean International Prostate Symptom Scores (IPSS) (22.3 vs 7.1 and 7.3, respectively; P <.01 for both), quality of life (QOL) (4.4 vs 1.2 and 1.3; P <.01 for both), and postvoid residual volume (196.7mL vs 92.1 and 61.2 mL; P <.01 and P <.01, respectively). Significant improvement was also seen in 3-month mean maximum urinary flow: 7.7 mL/s vs 12.8 mL/s (P <.01). One grade II complication of stroke occurred; all other complications were self-limited and grade I. Conclusions: PAE achieved a clinically and statistically significant improvement in symptom burden and secondary outcome measures in patients with PVs ≥ 80 mL. PAE may be an alternate treatment for patients for whom conventional surgical options are limited or associated with significant morbidity.",
author = "Shivank Bhatia and Sinha, {Vishal K.} and Sardis Harward and Christopher Gomez and Bruce Kava and Parekh, {Dipen J}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.jvir.2018.05.012",
language = "English (US)",
volume = "29",
pages = "1392--1398",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Prostate Artery Embolization in Patients with Prostate Volumes of 80 mL or More

T2 - A Single-Institution Retrospective Experience of 93 Patients

AU - Bhatia, Shivank

AU - Sinha, Vishal K.

AU - Harward, Sardis

AU - Gomez, Christopher

AU - Kava, Bruce

AU - Parekh, Dipen J

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose: To evaluate the safety and efficacy of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia for prostates ≥ 80 mL. Patients and Methods: A retrospective review was conducted of 93 patients with prostate volumes (PVs) ≥ 80 mL treated with PAE from April 2014 through October 2017. Mean patient age was 68.5 years (range 52–88) and mean age-adjusted Charlson comorbidity index was 3.2 (range 1–8). Exclusion criteria included history of biopsy-proven prostate cancer or catheter dependency. Clinical and urodynamic outcomes were reviewed at 1, 3, 6, and 12 months. Adverse events were graded according to the Clavien-Dindo classification. Results: Mean PV decreased significantly from 141.7 mL to 98.1 mL at 3 months (P <.01) and 82.2 mL at 12 months (P <.01). Significant improvements were seen in 3- and 12-month mean International Prostate Symptom Scores (IPSS) (22.3 vs 7.1 and 7.3, respectively; P <.01 for both), quality of life (QOL) (4.4 vs 1.2 and 1.3; P <.01 for both), and postvoid residual volume (196.7mL vs 92.1 and 61.2 mL; P <.01 and P <.01, respectively). Significant improvement was also seen in 3-month mean maximum urinary flow: 7.7 mL/s vs 12.8 mL/s (P <.01). One grade II complication of stroke occurred; all other complications were self-limited and grade I. Conclusions: PAE achieved a clinically and statistically significant improvement in symptom burden and secondary outcome measures in patients with PVs ≥ 80 mL. PAE may be an alternate treatment for patients for whom conventional surgical options are limited or associated with significant morbidity.

AB - Purpose: To evaluate the safety and efficacy of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia for prostates ≥ 80 mL. Patients and Methods: A retrospective review was conducted of 93 patients with prostate volumes (PVs) ≥ 80 mL treated with PAE from April 2014 through October 2017. Mean patient age was 68.5 years (range 52–88) and mean age-adjusted Charlson comorbidity index was 3.2 (range 1–8). Exclusion criteria included history of biopsy-proven prostate cancer or catheter dependency. Clinical and urodynamic outcomes were reviewed at 1, 3, 6, and 12 months. Adverse events were graded according to the Clavien-Dindo classification. Results: Mean PV decreased significantly from 141.7 mL to 98.1 mL at 3 months (P <.01) and 82.2 mL at 12 months (P <.01). Significant improvements were seen in 3- and 12-month mean International Prostate Symptom Scores (IPSS) (22.3 vs 7.1 and 7.3, respectively; P <.01 for both), quality of life (QOL) (4.4 vs 1.2 and 1.3; P <.01 for both), and postvoid residual volume (196.7mL vs 92.1 and 61.2 mL; P <.01 and P <.01, respectively). Significant improvement was also seen in 3-month mean maximum urinary flow: 7.7 mL/s vs 12.8 mL/s (P <.01). One grade II complication of stroke occurred; all other complications were self-limited and grade I. Conclusions: PAE achieved a clinically and statistically significant improvement in symptom burden and secondary outcome measures in patients with PVs ≥ 80 mL. PAE may be an alternate treatment for patients for whom conventional surgical options are limited or associated with significant morbidity.

UR - http://www.scopus.com/inward/record.url?scp=85053047007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053047007&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2018.05.012

DO - 10.1016/j.jvir.2018.05.012

M3 - Article

C2 - 30217744

AN - SCOPUS:85053047007

VL - 29

SP - 1392

EP - 1398

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 10

ER -